Font, A <br/><br/>
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  Aug 2002 
 - 213-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase I; Journal Article; Review 
<br/><br/><label>ISSN: </label>0169-5002 
<br/><br/><label>Standard No.: </label>10.1016/s0169-5002(02)00081-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Camptothecin--administration & dosage<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Carcinoma, Small Cell--drug therapy<br/>Carcinoma, Squamous Cell--drug therapy<br/>Docetaxel<br/>Dose-Response Relationship, Drug<br/>Female<br/>Head and Neck Neoplasms--drug therapy<br/>Humans<br/>Irinotecan<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Maximum Tolerated Dose<br/>Middle Aged<br/>Neoplasm Staging<br/>Paclitaxel--administration & dosage<br/>Taxoids<br/>Treatment Outcome